Next Article in Journal
Different Roles of GRP78 on Cell Proliferation and Apoptosis in Cartilage Development
Next Article in Special Issue
Nimbolide Induces ROS-Regulated Apoptosis and Inhibits Cell Migration in Osteosarcoma
Previous Article in Journal
Single-Base Pair Genome Editing in Human Cells by Using Site-Specific Endonucleases
Previous Article in Special Issue
Role of RUNX2 in Breast Carcinogenesis
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(9), 21138-21152;

PI3K and AKT: Unfaithful Partners in Cancer

Department of Visceral Surgery, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Pavillon 4, Av. de Beaumont, Lausanne 1011, Switzerland
Author to whom correspondence should be addressed.
Academic Editor: William Chi-shing Cho
Received: 25 July 2015 / Revised: 28 August 2015 / Accepted: 1 September 2015 / Published: 3 September 2015
(This article belongs to the Collection Advances in Molecular Oncology)
Full-Text   |   PDF [2008 KB, uploaded 3 September 2015]   |  


The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway regulates multiple cellular processes. An overactivation of the pathway is frequently present in human malignancies and plays a key role in cancer progression. Hence, its inhibition has become a promising approach in cancer therapy. However, the development of resistances, such as the abrogation of negative feedback mechanisms or the activation of other proliferative signaling pathways, has considerably limited the anticancer efficacy of PI3K/AKT inhibitors. In addition, emerging evidence points out that although AKT is acknowledged as the major downstream effector of PI3K, both PI3K and AKT can operate independently of each other in cancer, revealing another level of complexity in this pathway. Here, we highlight the complex relationship between PI3K and AKT in cancer and further discuss the consequences of this relationship for cancer therapy. View Full-Text
Keywords: cancer; signaling; PI3K; AKT; therapies cancer; signaling; PI3K; AKT; therapies

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Faes, S.; Dormond, O. PI3K and AKT: Unfaithful Partners in Cancer. Int. J. Mol. Sci. 2015, 16, 21138-21152.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top